Improving Tumor Oxygenation in Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00257829|
Recruitment Status : Withdrawn (This study was closed due to lack of funding.)
First Posted : November 23, 2005
Last Update Posted : February 29, 2008
The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are affected adversely by acidic pH. These effects have primarily been attributed to the presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to failure of radiotherapy to cure certain malignancies has had a chequered history. However, in recent years the evidence that hypoxia plays a central role in relative radioresistance has become more compelling.
Since approximately two-thirds of all women suffering from cervical carcinoma receive radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation resistance is critical to improving outcome among those with cervical cancer.
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer||Drug: Methazolamide Drug: Cisplatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Improving Tumor Oxygenation in Cervical Cancer With Methazolamide|
|Study Start Date :||July 2004|
- To assess the feasibility in improving tumor oxygenation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257829
|Principal Investigator:||Devansu Tewari, MD||Chao Family Comprehensive Cancer Center|